



Replacement Sheet

REP 1001 vs HSV-1




FIG. 1a

REP2001 vs HSV-1




FIG. 1b

REP3007 vs HSV-1





FIG. 1c

# Replacement Sheet



**FIG. 2**

# Replacement Sheet

FIG. 3a




FIG. 3b




FIG. 3c





FIG. 3d



Replacement Sheet

FIG. 3e




FIG. 3f





FIG. 3g



# Replacement Sheet




FIG. 4

Replacement Sheet

REP 2003 vs HSV-1




FIG. 5a

REP 2009 vs HSV-1




FIG. 5b

REP 2010 vs HSV-1




FIG. 5c

# Replacement Sheet

REP 2011 vs HSV-1




FIG. 5d

REP 2012 vs HSV-1




FIG. 5e

REP 2004 vs KOS




FIG. 5f

Replacement Sheet

REP 2006 vs HSV-1




FIG. 5g

REP 2007 vs HSV-1




FIG. 5h

REP 2008 vs KOS




FIG. 5i



Replacement Sheet




FIG. 6

Replacement Sheet




FIG. 7

Replacement Sheet

REP 2013 vs HSV-1




FIG. 8a

REP 2014 vs




FIG. 8b

REP 2015 vs HSV-1





FIG. 8c


# Replacement Sheet

## REP 2016 vs HSV-1




### FIG. 8d

## REP 2017 vs HSV-1



### FIG. 8e

## REP 2018 vs HSV-1



### FIG. 8f

Replacement Sheet

REP 2019 vs HSV-1




FIG. 8g

REP2020 vs HSV-1




FIG. 8h

REP 2121 vs HSV-1




FIG. 8i

Replacement Sheet






FIG. 9


Replacement Sheet



**FIG. 10**



**FIG. 11a**



**FIG. 11b**



Replacement Sheet

REP 2059 vs HSV-1




FIG. 11c

REP 2060 vs HSV-1




FIG. 11d

# Replacement Sheet

REP 1001 vs HSV-2




FIG. 12a

REP2001 vs HSV-2




FIG. 12b

REP3007 vs HSV-2





FIG. 12c

# Replacement Sheet



**FIG. 13**

# Replacement Sheet

FIG. 14a




FIG. 14b




FIG. 14c





FIG. 14d



# Replacement Sheet

FIG. 14e




FIG. 14f





FIG. 14g



Replacement Sheet




FIG. 15

# Replacement Sheet

REP 2004 vs CMV




FIG. 16a

REP 2006 vs CMV




FIG. 16b

Oligo size vs  $IC_{50}$  (CMV)




FIG. 16c

Replacement Sheet

Gancyclovir vs CMV




FIG. 17a

Foscarnet vs CMV




FIG. 17b

Cidofovir vs CMV




FIG. 17c



Replacement Sheet




FIG. 17d




FIG. 17e






FIG. 17f


# Replacement Sheet



**FIG. 17g**



**FIG. 17h**



**FIG. 17i**

Replacement Sheet

Oligo size vs IC50 (CMV)




FIG. 18

Replacement Sheet

REP 2004 vs HIV




FIG. 19a

REP 2006 vs HIV




FIG. 19b

Replacement Sheet

REP 2004 vs MT4 lymphocytes




FIG. 19c

REP 2006 vs MT4 lymphocytes




FIG. 19d

Replacement Sheet

Oligo size vs IC50 (HIV)




FIG. 20

## Amprenavir (Agenerase™)

Patient: 02-136820-1C0-0-AMP - Ref.: CNDO-0000092947-039-AMP - EP: 54




FIG. 21a

## Indinavir (Crixivan™)

Patient. 02-136820-1C0-0-IDV - Ref.. CNDO-0000092947-039-IDV - EP: 540




FIG. 21b

## Lopinavir (Kaletra™)




FIG. 21c

## Saquinavir (Fortovase™)




FIG. 21d



Replacement Sheet

## REP 2003

Patient: 02-136820-1C0-0-RP3 -- Ref.: CNDO-0000092947-039-RP3 -- EP: 541




FIG. 21e

## REP 2004

Patient 02-136820-1C0-0-RP4 -- Ref.: CNDO-0000092947-039-RP4 -- EP: 541





FIG. 21f


Replacement Sheet

**REP 2006**



**FIG. 21g**

**REP 2007**




**FIG. 21h**

# Replacement Sheet

Drug	IC50 (uM)
REP 2003	4.01
REP 2004	0.065
REP 2006	0.014
REP 2007	0.015
Amprenavir	0.016
Indinavir	0.006
Lopinavir	0.004
Saquinavir	0.003

**FIG. 22a**

**Oligo size vs IC50 (HIV-1)**



**FIG. 22b**

Replacement Sheet

## Amprenavir (Agenerase™)

Patient: 02-136823-1C0-D-AMP -- Ref: CNDO-0000092947-039-AMP -- EP: 54




FIG. 23a

## Indinavir (Crixivan™)

Patient: 02-136823-1C0-0-IDV -- Ref: CNDO-0000092947-039-IDV -- EP: 540




FIG. 23b

Replacement Sheet

## Lopinavir (Kaletra™)

Patient: 02-138823-1C0-0-LPV - Ref.: CNDO-0000092946-001-LPV - EP: 540




FIG. 23c

## Saquinavir (Fortovase™)

Patient 02-136823-1C0-0-SQV - Ref.: CNDO-0000092947-039-SQV - EP: 540




FIG. 23d

Replacement Sheet

## REP 2003

Patient 02-136823-1C0-0-RP3 - Ref.. CNDO-0000092947-039-RP3 - EP. 541




FIG. 23e

## REP 2004

Patient: 02-136823-1C0-0-RP4 - Ref: CNDO-0000092947-039-RP4 - EP: 541




FIG. 23f

## REP 2006

Patient: 02-136823-1C0-0-RP6 — Ref.: CNDO-0000092946-001-RP6 — EP: 546




FIG. 23g

## REP 2007

Patient 02-136823-1C0-0-RP7 — Ref.: CNDO-0000092947-039-RP7 — EP: 546




FIG. 23h

# Replacement Sheet

Drug	IC50 (uM)		Fold change in IC50
	HIV-1 NL4-3	HIV-1 MRDC4	
REP 2003	4.01	3.69	0.92
REP 2004	0.065	0.046	0.71
REP 2006	0.014	0.014	1.00
REP 2007	0.015	0.013	0.87
Amprenavir	0.017	0.065	3.82
Indinavir	0.006	0.08	13.33
Lopinavir	0.004	0.096	24.00
Saquinavir	0.003	0.006	2.00

**FIG. 24**



# Replacement Sheet

REP 2004 vs RSV




FIG. 25a

REP 2006 vs RSV




FIG. 25b

REP 2007 vs RSV





FIG. 25c


## Replacement Sheet

**Ribavirin vs RSV**




**FIG. 25d**

**REP 2004 vs Hep2 EC cells**



**FIG. 25e**

**REP 2006 vs Hep2 EC cells**



**FIG. 25f**

# Replacement Sheet




FIG. 25g




FIG. 25h

Replacement Sheet




FIG. 26

Replacement Sheet

REP 2006 vs COX B2




FIG. 27a

REP 2006 vs LLC-MK2 cells




FIG. 27b

# Replacement Sheet

FP Serum Interaction test with PS-ODN randomers of increasing size  
baseline (unbound bait): 86mP




FIG. 28a

REP2006 delivery with DOTAP in 293A cells over time  
(50% serum)




FIG. 28b

Competition test with REP 2006 encapsulated with DOTAP




FIG. 28d

REP2006 delivery with cytofectin in 293A cells over time  
(50% serum)




FIG. 28c

Competition test with REP 2006 encapsulated with Cytofectin





FIG. 28e


## Replacement Sheet

Bait size versus bait polarization (HSV-1)




**FIG. 29a**

Bait size versus bait polarization (HIV-1)



**FIG. 29b**

Bait size versus bait polarization (RSV)



**FIG. 29c**

Replacement Sheet

Oligo competitor size vs bait competition (HSV-1)




FIG. 30a

Oligo competitor size vs bait competition (HIV-1)




FIG. 30b

Oligo competitor size vs bait competition (RSV)




FIG. 30c



Replacement Sheet




FIG. 31

Replacement Sheet

Bait size vs p24 binding




FIG. 32a

Bait size vs gp41 binding




FIG. 32b




FIG. 33

Replacement Sheet




FIG. 34

## Replacement Sheet




FIG. 35a




FIG. 35b




FIG. 35c

# Replacement Sheet

## REPLICOR compounds versus Vaccinia






FIG. 36

**SEQUENCE COMPOSITION VS ANTI-HSV  
EFFICACY**



**FIG. 37a**

**Effect of sequence composition on efficiency  
against HSV-1**



**FIG. 37b**